GlassScriptPhysician profile
Amit Govil
NPI 1447208566
$298,288.46
in general payments reported to CMS, 2019-2025
18 companies · $60K in 2025
The $60K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $23K · 2021: $32K · 2022: $81K · 2023: $21K · 2024: $21K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $8,380 · Honoraria: $6,675 · Travel and Lodging: $6,082 · Food and Beverage: $4,030 · Education: $80.99 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,767.50 |
| Consulting Fee | $8,380.00 |
| Honoraria | $6,675.00 |
| Travel and Lodging | $6,081.89 |
| Food and Beverage | $4,030.43 |
| Education | $80.99 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $154,260.01 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $58,249.86 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $44,047.71 | 2021-2023 | Envarsus |
| Amgen INC. | $16,719.96 | 2023-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $8,707.07 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $6,840.00 | 2025 | |
| Akebia Therapeutics INC | $6,341.17 | 2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $2,062.48 | 2023 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $235.40 | 2024-2025 | Veltassa |
| Nxstage Medical, INC. | $185.08 | 2019-2025 | Nxstage System One, Pureflow Sl |
| Outset Medical INC | $100.13 | 2024 | |
| Novo Nordisk INC | $99.17 | 2025 | Rivfloza |
| Travere Therapeutics, INC. | $93.60 | 2023-2025 | |
| Pfizer INC. | $85.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.37 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $81.65 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Horizon Therapeutics Plc | $51.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $43.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Govil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.